Literature DB >> 23264511

The membrane as a target for controlling hypervirulent Clostridium difficile infections.

Xiaoqian Wu1, Philip T Cherian, Richard E Lee, Julian G Hurdle.   

Abstract

OBJECTIVES: The stationary phase of Clostridium difficile, which is primarily responsible for diarrhoeal symptoms, is refractory to antibiotic killing. We investigated whether disrupting the functions of the clostridial membrane is an approach to control C. difficile infections by promptly removing growing and non-growing cells.
METHODS: The bactericidal activities of various membrane-active agents were determined against C. difficile logarithmic-phase and stationary-phase cultures and compared with known antibiotics. Their effects on the synthesis of ATP, toxins A/B and sporulation were also determined. The effect of rodent caecal contents on anti-difficile activities was examined using two reutericyclin lead compounds, clofazimine, daptomycin and other comparator antibiotics.
RESULTS: Most membrane-active agents and partially daptomycin showed concentration-dependent killing of both logarithmic-phase and stationary-phase cultures. The exposure of cells to compounds at their MBC resulted in a rapid loss of viability with concomitant reductions in cellular ATP, toxins A/B and spore numbers. With the exception of nisin, these effects were not due to membrane pore formation. Interestingly, the activity of the proton ionophore nigericin significantly increased as the growth of C. difficile decreased, suggesting the importance of the proton gradient to the survival of non-growing cells. The activities of the lipophilic antimicrobials reutericyclins and clofazimine were reduced by caecal contents.
CONCLUSIONS: These findings indicate that C. difficile is uniquely susceptible to killing by molecules affecting its membrane function and bioenergetics, indicating that the clostridial membrane is a novel antimicrobial target for agents to alleviate the burden of C. difficile infections.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23264511      PMCID: PMC3695663          DOI: 10.1093/jac/dks493

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  57 in total

1.  Fidaxomicin failures in recurrent Clostridium difficile infection: a problem of timing.

Authors:  Robert Orenstein
Journal:  Clin Infect Dis       Date:  2012-05-18       Impact factor: 9.079

2.  Analysis of proline reduction in the nosocomial pathogen Clostridium difficile.

Authors:  Sarah Jackson; Mary Calos; Andrew Myers; William T Self
Journal:  J Bacteriol       Date:  2006-10-13       Impact factor: 3.490

3.  In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.

Authors:  Diane M Citron; Kerin L Tyrrell; C Vreni Merriam; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2011-12-19       Impact factor: 5.191

4.  Membrane-active antibacterial compounds.

Authors:  W A Hamilton
Journal:  Biochem J       Date:  1970-07       Impact factor: 3.857

5.  Comparative analysis of antimicrobial activities of valinomycin and cereulide, the Bacillus cereus emetic toxin.

Authors:  Marcel H Tempelaars; Susana Rodrigues; Tjakko Abee
Journal:  Appl Environ Microbiol       Date:  2011-02-25       Impact factor: 4.792

6.  Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis.

Authors:  R A Slayden; R E Lee; J W Armour; A M Cooper; I M Orme; P J Brennan; G S Besra
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

7.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences.

Authors:  Judith A O'Brien; Betsy J Lahue; J Jaime Caro; David M Davidson
Journal:  Infect Control Hosp Epidemiol       Date:  2007-10-03       Impact factor: 3.254

9.  Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

Authors:  Adam Belley; Eve Neesham-Grenon; Geoffrey McKay; Francis F Arhin; Robert Harris; Terry Beveridge; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

10.  Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.

Authors:  Julian G Hurdle; Raghunandan Yendapally; Dianqing Sun; Richard E Lee
Journal:  Antimicrob Agents Chemother       Date:  2009-07-06       Impact factor: 5.191

View more
  18 in total

1.  Chemical Genomics, Structure Elucidation, and in Vivo Studies of the Marine-Derived Anticlostridial Ecteinamycin.

Authors:  Thomas P Wyche; René F Ramos Alvarenga; Jeff S Piotrowski; Megan N Duster; Simone R Warrack; Gabriel Cornilescu; Travis J De Wolfe; Yanpeng Hou; Doug R Braun; Gregory A Ellis; Scott W Simpkins; Justin Nelson; Chad L Myers; James Steele; Hirotada Mori; Nasia Safdar; John L Markley; Scott R Rajski; Tim S Bugni
Journal:  ACS Chem Biol       Date:  2017-07-26       Impact factor: 5.100

2.  Action of nitroheterocyclic drugs against Clostridium difficile.

Authors:  Manish Kumar; Sudip Adhikari; Julian G Hurdle
Journal:  Int J Antimicrob Agents       Date:  2014-07-25       Impact factor: 5.283

3.  Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species.

Authors:  Hannah M Adams; Xiang Li; Carmela Mascio; Laurent Chesnel; Kelli L Palmer
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

4.  Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis.

Authors:  Clara Aguilar-Pérez; Begoña Gracia; Liliana Rodrigues; Asunción Vitoria; Rubén Cebrián; Nathalie Deboosère; Ok-Ryul Song; Priscille Brodin; Mercedes Maqueda; José A Aínsa
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

5.  Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile.

Authors:  Mohammed Zahidul Alam; Xiaoqian Wu; Carmela Mascio; Laurent Chesnel; Julian G Hurdle
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

6.  Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection.

Authors:  Philip T Cherian; Xiaoqian Wu; Lei Yang; Jerrod S Scarborough; Aman P Singh; Zahidul A Alam; Richard E Lee; Julian G Hurdle
Journal:  J Antimicrob Chemother       Date:  2015-08-18       Impact factor: 5.790

7.  Diarylacylhydrazones: Clostridium-selective antibacterials with activity against stationary-phase cells.

Authors:  Chao Chen; Naveen K Doll; Gabriele Casadei; John B Bremner; Kim Lewis; Michael J Kelso
Journal:  Bioorg Med Chem Lett       Date:  2013-12-10       Impact factor: 2.823

8.  Prospects for flavonoid and related phytochemicals as nature-inspired treatments for Clostridium difficile infection.

Authors:  X Wu; M Z Alam; L Feng; L S Tsutsumi; D Sun; J G Hurdle
Journal:  J Appl Microbiol       Date:  2014-01       Impact factor: 3.772

9.  The Clostridium difficile proline racemase is not essential for early logarithmic growth and infection.

Authors:  Xiaoqian Wu; Julian G Hurdle
Journal:  Can J Microbiol       Date:  2014-03-06       Impact factor: 2.419

10.  The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection.

Authors:  Ravi K R Marreddy; Xiaoqian Wu; Madhab Sapkota; Allan M Prior; Jesse A Jones; Dianqing Sun; Kirk E Hevener; Julian G Hurdle
Journal:  ACS Infect Dis       Date:  2018-12-13       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.